Leishmaniasis refers to illness arising from infection by any species of the protozoan parasite Leishmania, not merely parasitic presence, since most infected persons never develop symptoms [1][2]. It is a vector-borne disease transmitted through the bite of infected female sandflies and encompasses cutaneous, visceral, and mucocutaneous presentations [1][2]. Cutaneous leishmaniasis is typically a zoonotic infection maintained in wild or semi-domesticated animal reservoirs such as rodents and dogs [5].
Disease overview
ParasiticLeishmaniasis is a group of parasitic diseases caused by more than 20 Leishmania species and transmitted by female phlebotomine sandflies [1][2]. The three main clinical forms are cutaneous, visceral (kala-azar), and mucocutaneous, with cutaneous being the most common and visceral the most severe [1][2]. Globally, over 1 billion people live in endemic areas and are at risk, while cutaneous leishmaniasis alone affects around 12 million people with 2 million new cases yearly [3][2]. The World Health Organization classifies it as a neglected tropical disease that remains emerging and insufficiently controlled [3][4].
Read the full clinical and epidemiological profile 6
Cutaneous leishmaniasis produces skin lesions such as nodules, painless ulcers, crusted plaques, or ulcers on exposed body parts, sometimes numbering up to 200 and healing with permanent scars [1][2][5]. Visceral leishmaniasis (kala-azar) is life-threatening and marked by irregular fever, weight loss, anaemia, and enlargement of spleen and liver, with near-universal fatality if untreated [1][2]. Mucocutaneous leishmaniasis destroys mucous membranes of the nose, mouth, and throat, causing disability and social exclusion [1][2]. People living with HIV who acquire Leishmania infection face high likelihood of full disease, relapse, and death [4].
Leishmaniasis is endemic across almost 100 countries, with over 1 billion people at risk and cutaneous disease accounting for roughly 12 million existing and 2 million annual cases [3][2]. The Americas report about 80% of global cutaneous cases, and Brazil is the principal endemic country for visceral leishmaniasis in that region [4][2]. Visceral leishmaniasis is highly endemic in Iraq, Somalia, Sudan, and Yemen, while East Africa experiences frequent outbreaks of the visceral form and all types are endemic [4]. Cutaneous leishmaniasis is highly endemic in Algeria, whereas West Africa lacks sufficient epidemiological data, and imported cases mainly originate from Africa and the Americas [4]. Environmental and climatic changes, urbanization, deforestation, and migration further shape disease incidence and spread [4].
The parasites are transmitted to humans by the bite of infected female phlebotomine sandflies, tiny 2–3 mm insects that feed on blood to mature eggs [1][2]. More than 90 sandfly species are known vectors, and over 70 animal species including humans can serve as parasite reservoirs [4]. In most cases, cutaneous leishmaniasis is zoonotic, with transmission via Phlebotomus sandflies from rodent or dog reservoirs [5].
Control of leishmaniasis requires strengthened vector control, improved diagnostics, and development of safe and effective vaccines, which are currently lacking [3]. Because the disease primarily affects poor populations, commercial investment in diagnostics, drugs, and vaccines remains inadequate [3].
- 1 World Health Organization. Leishmaniasis [Internet]. cited 23 Oct 2026. Available from: https://www.who.int/news-room/questions-and-answers/item/leishmaniasis
- 2 World Health Organization. Leishmaniasis [Internet]. cited 23 Oct 2026. Available from: https://www.who.int/health-topics/leishmaniasis
- 3 de Vries HJC et al. Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments. Am J Clin Dermatol. 2022 Nov. PMID: 36103050. doi: 10.1007/s40257-022-00726-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/36103050/
- 4 World Health Organization. Leishmaniasis [Internet]. cited 23 Oct 2026. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
- 5 Mokni M et al. [Cutaneous leishmaniasis]. Ann Dermatol Venereol. 2019 Mar. PMID: 30879803. doi: 10.1016/j.annder.2019.02.002. PubMed: https://pubmed.ncbi.nlm.nih.gov/30879803/
- B55
- 1F51
Loading current data…
Country surveillance trends
Choose a country, source, and measure. Each line retains its published reporting period and definition.
Coverage
Reporting countries and regions
The map shows reporting coverage. Select a measure or open a shaded location to inspect its data.
Loading current data…
Surveillance pattern
Year × month seasonality by country
Review one country’s published monthly values by year. Empty cells indicate values the source did not publish.
Research Radar
Recent related research
A Diagnostic Algorithm Based on Urine Antigen and Blood Polymerase Chain Reaction Testing for Visceral Leishmaniasis in HIV-Coinfected Patients in Northwest Ethiopia
The American Journal of Tropical Medicine and Hygiene
Retrospective molecular screening reveals Leishmania (Leishmania) infantum in samples from patients investigated for suspected hematological neoplasms
Diagnostic Microbiology and Infectious Disease
7-(Chloroquinolin-4-yl) Sulfanyl Derivatives, Optimization of the Synthesis, In Silico ADMET Profiling Studies, and Evaluation of the Biological Activity Against Leishmania mexicana.
ChemMedChem
Nitrile-Based Leishmania Cysteine Protease B Inhibitors with In Vivo Efficacy against Visceral Leishmaniasis
ACS Omega
Temporal trends in reported vector-borne diseases in China before and after the onset of COVID-19 from 2004 to 2023
PLOS Neglected Tropical Diseases
Showing 5 of 114 related publications.
Literature links are provided for discovery and do not alter or validate the surveillance series above.
Loading official alerts…
Downloads and methods
Choose a time range and download CSV, JSON or XLSX files.

